LP
SRNE

LMR Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

LMR Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,709,500
Closed -$1.51M – 1267
2022
Q4 		$1.51M Buy
+1,709,500
New +$2.27M 0.03% 612

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

LMR Partners's SRNE Position: Q3 2017 in Review

LMR Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2017, closing a stake of 88,263 shares — an estimated $177K sold.

LMR Partners first reported a position in SRNE in Q1 2014 and held it in 2 quarters. The position peaked at $387K in Q1 2014. 37 funds tracked by Wall St. Rank hold SRNE as of Q3 2017.

  • LMR Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • LMR Partners sold 88,263 Sorrento Therapeutics, Inc. shares in Q3 2017, an estimated $177K.
  • LMR Partners first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 2 quarters.
  • LMR Partners's Sorrento Therapeutics, Inc. position peaked at $387K in Q1 2014.
  • 37 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.